Table 1.

Summary characteristics of studies included in meta-analysis.

Study number	References	Country	Continent	TB burden*	Study design	Samples	TBM/non-TBM patients recruited	PBMCs or CSFMCs/well	Test results
									TP	FP	FN	TN
1	Kim et al. (26)	Korea	Asia	Intermediate	Prospective	Peripheral blood	11/24	2.5 × 105	10	9	1	15
						Cerebrospinal fluid	4/12	2.5 × 105	3	3	1	9
2	Thomas et al. (27)	India, UK, Germany	Asia and Europe	High†	Prospective	Peripheral blood	11/8	2.5 × 105	9	2	2	6
						Cerebrospinal fluid	10/7	2.5 × 105	9	0	1	7
3	Kim et al. (28)	Korea	Asia	Intermediate	Prospective	Peripheral blood	31/53	2.5 × 105	22	23	9	30
						Cerebrospinal fluid	22/28	2.5 × 105	13	3	9	25
4	Patel et al. (29)	South Africa	Africa	High	Prospective	Peripheral blood	37/50	2.5 × 105	33	33	4	17
						Cerebrospinal fluid	38/48	3 × 104 -2.5 × 105	32	13	6	35
5	Cho et al. (30)	Korea	Asia	Intermediate	Prospective	Peripheral blood	35/87	2.5 × 105	26	47	9	40
6	Park et al. (31)	Korea	Asia	Intermediate	Prospective	Peripheral blood	25/57	2.5 × 105	22	24	3	33
						Cerebrospinal fluid	25/57	2.5 × 105	18	12	7	45
7	Zhang et al. (32)	China	Asia	High	Retrospective	Peripheral blood	30/30	2.5 × 105	23	4	7	26
						Cerebrospinal fluid	30/30	1 × 104	28	1	2	29
8	Chen et al. (33)	China	Asia	High	Retrospective	Peripheral blood	40/18	2.5 × 105	27	2	13	16
9	Lu et al. (34)	China	Asia	High	Retrospective	Peripheral blood	30/39	2.5 × 105	21	5	9	34
10	Lv et al. (35)	China	Asia	High	Retrospective	Peripheral blood	32/27	2.5 × 105	23	4	9	23
11	Mou et al. (36)	China	Asia	High	Retrospective	Cerebrospinal fluid	47/45	2.5 × 105	38	5	9	40
12	Qin et al. (37)	China	Asia	High	Prospective	Peripheral blood	12/28	2.5 × 105	10	5	2	23
						Cerebrospinal fluid	12/28	≤2.5 × 105	11	2	1	26
13	Cui et al. (38)	China	Asia	High	Retrospective	Peripheral blood	40/66	2.5 × 105	29	9	11	57
						Cerebrospinal fluid	40/66	1 × 104	38	5	2	61
14	Li et al. (39)	China	Asia	High	Retrospective	Peripheral blood	53/36	2.5 × 105	48	9	5	27
						Cerebrospinal fluid	53/36	2.5 × 105	38	3	15	33
15	Lu et al. (40)	China	Asia	High	Retrospective	Peripheral blood	30/39	2.5 × 105	21	5	9	34
16	Park et al. (41)	Korea	Asia	Intermediate	Prospective	Peripheral blood	46/159	2.5 × 105	38	66	8	93
						Cerebrospinal fluid	38/109	2.5 × 105	28	16	10	93
17	Wang et al. (42)	China	Asia	High	Retrospective	Peripheral blood	54/34	2.5 × 105	45	10	9	24
18	Li et al. (43)	China	Asia	High	Retrospective	Cerebrospinal fluid	52/44	2.5 × 105	51	10	1	34
19	Lu et al. (44)	China	Asia	High	Retrospective	Peripheral blood	61/85	2.5 × 105	38	23	23	62
20	Ma et al. (45)	China	Asia	High	Retrospective	Peripheral blood	74/80	2.5 × 105	56	33	18	47
21	Pan et al. (46)	China	Asia	High	Prospective	Peripheral blood	53/37	2.5 × 105	48	9	5	28
						Cerebrospinal fluid	51/36	1 × 105-2.5 × 105	31	1	20	35
22	Wang et al. (47)	China	Asia	High	Retrospective	Peripheral blood	29/36	2.5 × 105	26	9	3	27
23	Song et al. (48)	China	Asia	High	Retrospective	Peripheral blood	76/57	2.5 × 105	59	9	17	48
						Cerebrospinal fluid	76/57	2.5 × 105	48	1	28	56
24	Wu et al. (49)	China	Asia	High	Retrospective	Peripheral blood	55/76	2.5 × 105	45	18	10	58
25	Yang et al. (50)	China	Asia	High	Retrospective	Peripheral blood	30/66	2.5 × 105	28	15	2	51
						Cerebrospinal fluid	30/66	2.5 × 105	20	8	10	58
26	Kwon et al. (51)	Korea	Asia	Intermediate	Prospective	Peripheral blood	10/45	2.5 × 105	5	10	5	35
						Cerebrospinal fluid	10/45	2.5 × 105	3	4	7	41
27	Xu et al. (52)	China	Asia	High	Retrospective	Peripheral blood	84/86	2.5 × 105	63	35	21	51

^*Refer to Global Tuberculosis Report 2019; Most participants were enrolled in India. TB, tuberculosis; TBM, tuberculous meningitis; PBMCs, peripheral blood mononuclear cells; CSFMCs, cerebrospinal fluid mononuclear cells; TP, true positive; FP, false positive; FN, false negative; TN, true negative.